Get the Stockscreener App
0.4486
3.05%
-0.0144
Bluebird Bio Inc stock is traded at $0.4486, with a volume of 3.93M.
It is down -3.05% in the last 24 hours and down -21.25% over the past month.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
See More
Previous Close:
$0.463
Open:
$0.46
24h Volume:
3.93M
Relative Volume:
0.55
Market Cap:
$88.50M
Revenue:
$21.73M
Net Income/Loss:
$-91.17M
P/E Ratio:
-0.4398
EPS:
-1.02
Net Cash Flow:
$-286.43M
1W Performance:
-8.72%
1M Performance:
-21.25%
6M Performance:
-50.11%
1Y Performance:
-87.10%
1-Day Range:
$0.4454
$0.4693
1-Week Range:
$0.4454
$0.499
52-Week Range:
$0.4454
$5.53
Bluebird Bio Inc Stock (BLUE) Company Profile
Name
Bluebird Bio Inc
Sector
Industry
Phone
339-499-9300
Address
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-23 | Initiated | JP Morgan | Overweight |
| Mar-07-23 | Initiated | Robert W. Baird | Outperform |
| Aug-05-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-02-22 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-06-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-07-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-08-21 | Reiterated | Barclays | Equal Weight |
| Nov-08-21 | Reiterated | Canaccord Genuity | Hold |
| Nov-08-21 | Downgrade | Goldman | Neutral → Sell |
| Nov-08-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Nov-08-21 | Reiterated | Wedbush | Neutral |
| Nov-08-21 | Reiterated | Wells Fargo | Equal Weight |
| Aug-10-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-10-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-10-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-10-21 | Resumed | William Blair | Mkt Perform |
| Aug-09-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Mar-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Feb-17-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-16-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-16-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-09-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-05-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-05-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-05-20 | Downgrade | Stifel | Buy → Hold |
| Nov-02-20 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-20-20 | Initiated | Mizuho | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-27-20 | Upgrade | Stifel | Hold → Buy |
| Feb-19-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Feb-03-20 | Resumed | BofA/Merrill | Buy |
| Feb-03-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-13-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-19-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-04-19 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-01-19 | Initiated | Stifel | Hold |
| Aug-12-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-19 | Upgrade | Maxim Group | Hold → Buy |
View All
Bluebird Bio Inc Stock (BLUE) Latest News
Bluebird bio stock plunges to 52-week low of $0.45 amid downturn - Investing.com
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
Vanguard Group Inc's Strategic Acquisition of Shares in bluebird bio Inc - GuruFocus.com
bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com - MarketBeat
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
7 children given bluebird's Skysona developed blood cancer: study - MSN
bluebird bio (BLUE): Promising Gene Editing Stock with FDA-Approved Therapies - Insider Monkey
bluebird bio, Inc. (NASDAQ:BLUE) Receives $4.63 Consensus PT from Analysts - MarketBeat
The Ultimate Biotech Stock to Buy With $50 Right Now - The Motley Fool
bluebird bio (NASDAQ:BLUE) Receives New Coverage from Analysts at StockNews.com - MarketBeat
bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com - MarketBeat
BLUE (bluebird bio) Cyclically Adjusted Revenue per Share : $0.48 (As of Jun. 2024) - GuruFocus.com
Hematological Malignancies Detected in Some Patients Treated With bluebird bio’s Active Cerebral Adrenoleukodystrophy Gene Therapy Eli-Cel - CGTLive™
Research details seven cases of blood cancer linked to Skysona - The Pharma Letter
Millennium Management LLC Sells 1,092,888 Shares of bluebird bio, Inc. (NASDAQ:BLUE) - MarketBeat
Worries Mount Over Cancer Risks in Bluebird Bio's Gene Therapy - Yahoo Finance
Skysona safety concerns unlikely to affect bluebird bio's stock, says Baird - Investing.com Canada
7 children given bluebird's Skysona developed blood cancer: study (NASDAQ:BLUE) - Seeking Alpha
Bluebird bio’s Skysona led to seven cases of blood cancer in gene therapy trials - Yahoo Finance
New data underline cancer risk of Bluebird therapy for brain disease - BioPharma Dive
Gene Therapy For Rare Disease Market Report: Growth Forecast - openPR
Adrenoleukodystrophy Market to Rise by 2034 | bluebird bio, - openPR
Bluebird Bio (BLUE) Stock Dips Amid Market Volatility - GuruFocus.com
Renaissance Technologies LLC Reduces Stake in bluebird bio, Inc. (NASDAQ:BLUE) - MarketBeat
StockNews.com Begins Coverage on bluebird bio (NASDAQ:BLUE) - MarketBeat
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
bluebird bio, Inc. (NASDAQ:BLUE) Given Average Rating of "Hold" by Brokerages - MarketBeat
FY2024 EPS Estimates for bluebird bio, Inc. (NASDAQ:BLUE) Cut by Cantor Fitzgerald - MarketBeat
bluebird bio, Inc. to Post FY2024 Earnings of ($1.40) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:BLUE) - Defense World
Bluebird Bio CEO sells shares worth over $18k By Investing.com - Investing.com South Africa
Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace
Bluebird Bio exec sells shares to cover taxes, acquires new stock By Investing.com - Investing.com South Africa
Bluebird Bio exec sells shares to cover taxes, acquires new stock - Investing.com India
Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements - GuruFocus.com
Bluebird bio stock plunges to 52-week low of $0.46 By Investing.com - Investing.com Canada
Bluebird bio stock plunges to 52-week low of $0.46 - Investing.com
Biotech layoff tracker: 13 biotechs cut over 1,400 jobs - The Business Journals
Bluebird bio to cut 25% of jobs in fresh bid to battle cash crunch - AOL
bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing - StockTitan
Bluebird: Q2 Earnings Snapshot - San Antonio Express-News
Bluebird Bio Inc Stock (BLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):